Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Journal:
The Lancet
Published:
Affiliations:
26
Authors:
21
Institutions Authors Share
Pfizer, United States of America (USA)
4.000000
0.19
Pontifical Catholic University of Rio Grande do Sul (PUCRS), Brazil
1.000000
0.05
Hospital of the University of Montreal (CHUM), Canada
1.000000
0.05
Vall d'Hebron University Hospital (HUVH), ICS, Spain
1.000000
0.05
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA)
1.000000
0.05
START Carolinas, United States of America (USA)
1.000000
0.05
National Cancer Center Hospital East, Japan
1.000000
0.05
National Center for Tumor Diseases (NCT) Heidelberg, Germany
1.000000
0.05
Arizona Urology Specialists, United States of America (USA)
1.000000
0.05
UiO Akershus University Hospital (Ahus), Norway
1.000000
0.05
National Cancer Center (NCC), South Korea
1.000000
0.05
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Italy
1.000000
0.05
Peter MacCallum Cancer Centre (Peter Mac), Australia
1.000000
0.05
University of Glasgow, United Kingdom (UK)
0.500000
0.02
Beatson West of Scotland Cancer Centre (BWoSCC), United Kingdom (UK)
0.500000
0.02
Institute Gustave-Roussy (IGR), France
0.500000
0.02
Centre Oscar Lambret, France
0.500000
0.02
Victor Hugo Clinic, France
0.500000
0.02
Centre Jean Bernard, France
0.500000
0.02
Auckland City Hospital (ACH), New Zealand
0.500000
0.02
The University of Auckland, New Zealand
0.500000
0.02
Europejskie Centrum Zdrowia Otwock sp. z o.o., Poland
0.500000
0.02
Medical Centre of Postgraduate Education (CMKP), Poland
0.500000
0.02